Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies

Expert Review of Anticancer Therapy

Volumn 7, Issue 2, 2007, Pages 169-181

  Lamoureux, François ^a   Trichet, Valérie ^a   Chipoy, Céline ^a   Blanchard, Frédéric ^a   Gouin, François ^a,b   Redini, Françoise ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b HÔTEL DIEU   (France)

Author keywords

Bisphosphonate; New target; Osteoprotegerin; Osteosarcoma; Therapy; Tumor biology; Tumor microenvironment

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; DOXORUBICIN; ENDOTHELIN 1; ENZYME; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN CONVERTING ENZYME; LEXIDRONAM SAMARIUM SM 153; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PROTEIN P53; RAPAMYCIN; SOMATOMEDIN C; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; BONE TUMOR; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG METASTASIS; MEDICAL DOCUMENTATION; MICROENVIRONMENT; MONOTHERAPY; NONHUMAN; ONSET AGE; OSTEOSARCOMA; PATHOPHYSIOLOGY; REVIEW; SUICIDE GENE THERAPY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 33847114438     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.2.169     Document Type: Review

References (88)

1. Mertens F, Mandahl N, Orndal C et al. Cytogenetic findings in 33 osteosarcomas. Int. J. Cancer 55(1), 44-50 (1993).
2. Klein MJ, Siegal GP. Osteosarcoma. Anatomic and histologic variants. Am. J. Clin. Pathol. 125(4), 555-581 (2006).
3. Unni KK. Osteosarcoma of bone. J. Orthop. Sci. 3(5), 287-294 (1998).
4. Okada K, Frassika FJ, Sim SH et al. Parosteal osteosarcoma. A clinicopathological study. J. Bone Joint Surg. Am. 76(3), 366-378 (1994).
5. Cotterill SJ, Wright CM, Pearce MS et al. Stature of young people with malignant bone tumors. Pediatr. Blood Cancer 42(1), 59-63 (2004).
6. Longhi A, Pasini A, Cicognani A et al. Height as a risk factor for osteosarcoma. J. Pediatr. Hematol. Oncol. 27(6), 314-318 (2005).
7. Aisen AM, Martel W, Braunstein EM et al. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am. J. Roentgenol. 146(4), 749-756 (1986).
8. Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J. Magn. Reson. Imaging 5(6), 689-694 (1999).
9. Rigo P, Paulus P. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur. J. Nucl. Med. 23(12), 1641-1674 (1996).
10. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenic sarcoma. Cancer 37(1), 1-11 (1976).
11. Campanacci M, Bacci G, Bertoni F et al. The treatment of osteosarcoma of the extremities: twenty year's experience at Istituto Rizzoli. Cancer 48(7), 1569-1581 (1981).
12. Rosenburg SA, Chabner BA, Young RC. Treatment of osteogenic sarcoma. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat. Rep. 63(5), 739-751 (1979).
13. Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49(6), 1221-1230 (1982).
14. Bacci G, Bettoni F, Longhi A et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97(12), 3068-3075 (2003).
15. Wifa H, Grimer RJ. Surgical options and outcomes in bone sarcoma. Expert Rev. Anticancer Ther. 6(2), 239-248 (2006).
16. Souhami RL, Craft AW, van der Eijken JW et al. Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350(9082), 911-917 (1997).
17. Bacci G, Ferrari S, Bertoni F et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Orthopedico Rizzoli according to the IOR/OS2 protocol: an update report. J. Clin. Oncol. 18(24), 4016-4027 (2000).
18. Delaney TF, Park L, Goldberg SI et al. Radiotherapy for local control of osteosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 61(2), 492-498 (2005).
19. Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober O. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin 38(8), 337-340 (1999).
20. Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin. Pharmacother. 7(11), 1475-1486 (2006).
21. Whelan JS, Burcombe RJ, Janinis J et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumors. Ann. Oncol. 13(1), 23-30 (2002).
22. Masucci G, Wersall P, Ragnhammar P, Mellstedt H. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 29(4), 288-292 (1989).
23. Edmonson JH, Long HJ, Kvols LK et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann. Oncol. 8(7), 637-641 (1997).
24. Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5(9), 2316-2323 (1999).
25. Rao RD, Anderson PM, Arndt CA et al. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am. J. Clin. Oncol. 26(5), 493-498 (2003).
26. Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5(9), 2316-2323 (1999).
27. Kleinerman ES, Gano JB, Johnston DA et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18(2), 93-99 (1995).
28. Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high dose methotrexate. J. Clin. Oncol. 23(9), 2004-2011 (2005).
29. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-α in solid turmours: part 1. BioDrugs 16(4), 261-281 (2002).
30. Jia SF, An T, Worth L, Kleinerman ES. Interferon-α enhances the sensitivity of human osteosarcoma cells to etoposide. J. Interferon Cytokine Res. 19(6), 617-627 (1999).
31. Strander H, Bauer HC, Brosjo O et al. Long-term adjuvant interferon treatment of human osteosarcoma: a pilot study. Acta Oncol. 34(6), 877-880 (1995).
32. Nilsonne U, Brostrom LA, Aparisi T. Local tumour resection in interferon treated osteosarcoma patients. Ann. Chir. Gynaecol. 84(1), 63-70 (1995).
33. Winkler K, Beron G, Kotz R et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J. Clin. Oncol. 2(6), 617-624 (1984).
34. Edmonson JH, Long HJ, Frytak S et al. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treat. Rep. 71(7-8), 747-748 (1987).
35. Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group SSGVIII study: prognostic factors for outcome and role of replacement salvage chemotherapy for poor histologic responders. Eur. J. Cancer 39(4), 488-494 (2003).
36. Luksch R, Perotti D, Cefalo G et al. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 89(3), 263-268 (2003).
37. Liebeau C, Roesel C, Schmidt S et al. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res. 24(5A), 2861-2867 (2004).
38. Jia SF, Worth LL, Densmore CL et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res. 9(9), 3462-3468 (2003).
39. Duan X, Jia SF, Zhou Z, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106(6), 1382-1388 (2006).
40. Theoleyre S, Mori K, Cherrier B et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 5, 123-132 (2005).
41. Joyama, S, Naka N, Tsukamoto Y et al. Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin. Orthop. Relat. Res. (2006) (Epub ahead of print).
42. Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8(9), 619-627 (2001).
43. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 4(4), 625-631 (2005).
44. Song SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp. Mol. Med. 33(1), 46-53 (2001).
45. Ganjavi H, Gee M, Narendran A et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 13(4), 415-419 (2006).
46. Benjamin R, Helman L, Meyers P, Reaman G. A Phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum. Gene Ther. 12(12), 1591-1593 (2001).
47. Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 55(23), 5493-5498 (1995).
48. Chen DS, Zhu NL, Hung G et al. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice. Hum. Gene Ther. 8(14), 1667-1674 (1997).
49. Ketola A, Maatta AM, Pasanen T, Tulimaki & Wahlfors J. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy. Int. J. Mol. Med. 13(5), 705-710 (2004).
50. Pellinen R, Hakkarainer T, Wahlfors J et al. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int. J. Oncol. 25(6), 1753-1762 (2004).
51. Ko SC, Cheon J, Kao C et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56(20), 4614-4619 (1996).
52. Cheon J, Ko SC, Gardner TA et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4(6), 359-365 (1997).
53. Grossin L, Charissoux JL, Teissier MP, Rigaux M. Selective killing of osteosarcoma cells in culture after retroviral mediated gene transfer of a herpes simplex thymidine kinase suicide gene. Anticancer Res. 19(1A), 71-76 (1999).
54. Dong D, Dubeau L, Bading J et al. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. Hum. Gene Ther. 15(6), 553-561 (2004).
55. Sulzbacher I, Birner P, Trieb A, Lańg S, Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch. 441(4), 345-349 (2002).
56. Lee YH, Tokunaga T, Oshika Y et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur. J. Cancer 35(7), 1089-1093 (1999).
57. Kaya M, Wada M, Kawagushi S et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br. J. Cancer 86(6), 864-869 (2002).
58. Dutour A, Monteil J, Paraf F et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol. Ther. 11(2), 311-319 (2005).
59. Kappel CC, Velez-Yanquas SC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 54(10), 2803-2807 (1994).
60. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int. J. Cancer 65(6), 870-874 (1996).
61. Mansky PJ, Liewehr DJ, Steinberg SM et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J. Pediatr. Hematol. Oncol. 24(6), 440-446 (2002).
62. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of osteosarcoma. J. Clin. Oncol. 22(9), 1706-1712 (2004).
63. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198(2-3), 165-184 (1994).
64. Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17(9), 2781-2788 (1999).
65. Bagatell R, Beliakoff J, David CL et al. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer 113(2), 179-188 (2005).
66. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of Endothelin-1. Clin. Orthop. Relat. Res. 415(Suppl.), S67-S74 (2003).
67. Lavardiere C, Hoang BH, Yang R et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin. Cancer Res. 11(7), 2561-2567 (2005).
68. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a routine model of osteosarcoma. Cancer Res. 65(6), 2406-2411 (2005).
69. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer 82(4), 973-980 (2000).
70. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 10(2), 159-178 (2000).
71. O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin. Orthop. Relat. Res. 415(Suppl.), S100-S104 (2003).
72. Guise TA. Yin JJ, Mohammad KS. Role of Endothelin-1 in osteoblastic bone metastases. Cancer 97(Suppl. 3), 779-784 (2003).
73. Heymann D, Ory B, Gouin F, Green JR, Rédini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol. Med. 10(7), 337-343 (2004).
74. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296(2), 235-242 (2001).
75. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl. 12), 2961-2978 (2000).
76. Berenson J, Rosen L, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic lesions. Cancer 91(10), 1191-1200 (2001).
77. Lipton A. Bisphosphonates and breast carcinoma. Cancer 88(Suppl. 12), 3033-3037 (2000).
78. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002).
79. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer 84(7), 951-958 (2001).
80. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12(5), 459-465 (2001).
81. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33(2), 216-228 (2003).
82. Heymann D, Ory B, Blanchard F et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37(1), 74-86 (2005).
83. Ory B, Heymann M-F, Kamijo A et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104(11), 2522-2529 (2005).
84. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Rédini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15(6), 457-475 (2004).
85. Croucher PI, Shipman CM, Lippitt J et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98(13), 3534-3540 (2001).
86. Morony S, Cappareli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61(11), 4432-4436 (2001).
87. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-572 (1889).
88. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J. Musculoskelet. Neuronal Interact. 4(3), 308-318 (2004).